Want to see HK:2877 full AI Analyst Report?
2877 Stock Chart & Stats
HK$8.26
HK$0.10(1.21%)
At close: 4:00 PM EDT
HK$8.26
HK$0.10(1.21%)
Day’s Range― - ―
52-Week RangeHK$7.21 - HK$10.47
Previous CloseN/A
Volume411.00K
Average Volume (3M)1.29M
Market Cap
HK$6.08B
Enterprise Value-HK$1.56K
Total Cash (Recent Filing)HK$7.57B
Total Debt (Recent Filing)HK$335.05M
Price to Earnings (P/E)5.5
Beta0.57
Next Earnings
Sep 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield7.54%
Share Statistics
EPS (TTM)1.25
Shares Outstanding827,000,000
10 Day Avg. Volume1,790,900
30 Day Avg. Volume1,290,900
Financial Highlights & Ratios
PEG Ratio0.45
Price to Book (P/B)0.72
Price to Sales (P/S)1.86
P/FCF Ratio5.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.27
Revenue Forecast (FY)HK$3.03B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetExtremely low leverage provides durable financial flexibility: the company can fund R&D, manufacturing scale-up, and dividends from internal resources, withstand industry shocks with limited refinancing risk, and avoid interest-driven margin erosion over the next several quarters.
High And Stable MarginsPersistently elevated gross and operating margins reflect pricing power from branded proprietary medicines and efficient manufacturing. High structural margins support strong cash conversion and ROE, allowing reinvestment or shareholder returns even if top-line growth softens.
Positive Free Cash FlowConsistent, improving free cash flow underpins long-term solvency and strategic optionality: it funds capex, product development, dividends or acquisitions without reliance on debt, reducing execution risk and making financing of growth initiatives self-sustaining.
Bears Say
Declining Revenue TrendSustained top-line contraction reduces operating leverage and scale advantages, pressuring future profit pools. If revenue erosion persists, it could force cuts to R&D or marketing, impair long-term product pipeline development, and constrain sustainable growth beyond the next several quarters.
Easing Profitability From PeakMargin softening from the 2023 high suggests emerging pricing pressure, mix shifts, or cost inflation that may not be transitory. Lower sustainable margins would weaken cash generation and ROE, reducing investment capacity and increasing sensitivity to competitive or regulatory shocks.
Product Concentration RiskHeavy reliance on branded TCM for cardiovascular/cerebrovascular indications concentrates commercial and regulatory risk. A narrow therapeutic focus makes revenues sensitive to competitive incumbents, guideline changes, or reimbursement shifts, limiting diversification over the medium term.
China Shineway Pharmaceutical Group Limited News
2877 FAQ
What was China Shineway Pharmaceutical Group Limited’s price range in the past 12 months?
China Shineway Pharmaceutical Group Limited lowest stock price was HK$7.21 and its highest was HK$10.47 in the past 12 months.
What is China Shineway Pharmaceutical Group Limited’s market cap?
China Shineway Pharmaceutical Group Limited’s market cap is HK$6.08B.
When is China Shineway Pharmaceutical Group Limited’s upcoming earnings report date?
China Shineway Pharmaceutical Group Limited’s upcoming earnings report date is Sep 01, 2026 which is in 16 days.
How were China Shineway Pharmaceutical Group Limited’s earnings last quarter?
China Shineway Pharmaceutical Group Limited released its earnings results on Mar 27, 2026. The company reported HK$0.486 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is China Shineway Pharmaceutical Group Limited overvalued?
According to Wall Street analysts China Shineway Pharmaceutical Group Limited’s price is currently Overvalued.
Does China Shineway Pharmaceutical Group Limited pay dividends?
China Shineway Pharmaceutical Group Limited pays a Semiannually dividend of HK$0.487 which represents an annual dividend yield of 7.54%. See more information on China Shineway Pharmaceutical Group Limited dividends here
What is China Shineway Pharmaceutical Group Limited’s EPS estimate?
China Shineway Pharmaceutical Group Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does China Shineway Pharmaceutical Group Limited have?
China Shineway Pharmaceutical Group Limited has 827,000,000 shares outstanding.
What happened to China Shineway Pharmaceutical Group Limited’s price movement after its last earnings report?
China Shineway Pharmaceutical Group Limited reported an EPS of HK$0.486 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 6.483%.
Which hedge fund is a major shareholder of China Shineway Pharmaceutical Group Limited?
Currently, no hedge funds are holding shares in HK:2877
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
China Shineway Pharmaceutical Group Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-6.07%
12-Months-Change
Fundamentals
Return on Equity
7.54%
Trailing 12-Months
Asset Growth
12.33%
Trailing 12-Months
Company Description
China Shineway Pharmaceutical Group Limited
As an investment holding enterprise, China Shineway Pharmaceutical Group Limited is dedicated to the development, production, and sale of traditional Chinese medicines throughout the People's Republic of China and Hong Kong. Its extensive product range includes modern Chinese pharmaceuticals delivered as soft capsules, granular preparations, and injectable forms, alongside specialized Traditional Chinese Medicine (TCM) Formula Granules. These offerings cater to a broad spectrum of therapeutic needs, such as cardiovascular and cerebrovascular health, anti-viral applications, orthopedic conditions, pediatric ailments, gynecological care, and gastrointestinal issues. Furthermore, the company is involved in the trading of agricultural commodities. Founded in 2004, its headquarters are situated in Shijiazhuang, PRC, and it functions as a subsidiary of Forway Investment Limited.
Technical Analysis
The United Laboratories International Holdings
―
China Traditional Chinese Medicine Holdings Co
―
Jacobson Pharma Corporation Limited
―
Grand Pharmaceutical Group Limited
―
Shandong Xinhua Pharmaceutical Company Limited Class H
―